Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer

INTRODUCTION. A KRAS mutation represented the first genomic biomarker to predict lack of benefit from anti-epidermal growth factor receptor (EGFR) antibody therapy in advanced colorectal cancer (CRC). Expanded RAS testing has further refined the treatment approach, but understanding of genomic alter...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Rankin, Andrew, Klempner, Samuel J., Erlich, Rachel, Sun, James X., Grothey, Axel, Fakih, Marwan, George, Thomas J., Lee, Jeeyun, Ross, Jeffrey S., Stephens, Philip J., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B.
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2016
Sujets:
Cancer Diagnostics and Molecular Pathology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5189622/
https://ncbi.nlm.nih.gov/pubmed/27682134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0148
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires